Boris Räber joins Advokatur am Rosenberg from Walder Wyss, where he becomes a partner. He has many years of experience in national and international m&a transactions as well as private equity and
Tags :Vischer
As we have informed here, Invision, a renowned investment company focusing on succession solutions and growth financing for medium-sized companies in German-speaking countries, has launched and successfully closed Invision Logistics LP, a CHF 145m continuation
Resistell, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round
Jonas D. Gassmann has been promoted to counsel and new head of white-collar crime at VISCHER effective from 1 January 2023. Gassmann is an attorney at law who specialises in intellectual property law and white-collar crime. Media
As we have informed last 15th December 2022 here, L-GAM, a mid-market private equity investment firm, has invested in Cotta Group, headquartered in Bendern (Liechtenstein), alongside Peter Gschwend. AFINUM has sold its stake in Cotta Collection
As we have informed last 15 November 2022 here, Hangzhou GreatStar Industrial, whose A Shares are listed on the Shenzhen Stock Exchange, became the eighth Chinese company that has listed global depositary receipts (GDRs) on the SIX
Anokion, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. Founded in Switzerland and based
Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies, a privately owned Swiss company spun out from EPFL. The financing was realised in form of private bonds with warrants which can be
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio
VISCHER has advised Forty51 Ventures, a Biotech venture capital firm, on its first fund, Forty51 Ventures Fund I which has raised USD 43 million in a first closing and is domiciled in Luxemburg. VISCHER has supported,
